- Employers: Entry-Level Applicants Are Just About Useless
- Walmart vs. Costco: How Do They Really Compare?
- Tesla Pops on GM Rumor (Update 1)
- Putting a Fingerprint on Every Bullet
- Why Apple Sucks as an Investment, but Amazon Doesn't
Article
Unigene Faces Do-or-Die FDA Panel Tuesday
An FDA panel's decision on the safety of calcitonin to treat osteoporosis will have a big impact on Unigene's stock price.
06:00AM 03/04/13
Article
Gauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results
TheStreet contributor Aafia Chaudhry says prior study results raise the risk of a bad outcome in Ziopharm's phase III sarcoma drug trial.
06:00AM 02/19/13
Article
Sarepta Bear Speaks: Eteplirsen Accelerated Approval Will Be Denied
Eteplirsen data are biased and flimsy, and FDA will ask for another clinical trial, says TheStreet contributor Aafia Chaudhry.
07:00AM 02/11/13
Article
Depomed Bear Case: FDA Panel Will Ding Serada
New contributor Aafia Chaudhry explains why she believes Depomed's hot flash drug has no future.
08:35AM 02/04/13
« Back
Page 1 of 1
Next »